References
1
Argoudelis AD.
Reusser F.
Whaley HA.
Baczynskyj L.
Mizsak SA.
Wnuk RJ.
J. Antibiot.
1976,
29:
1001
2
Reusser F.
Biochemistry
1977,
16:
3406
3
Kuo M.-S.
Yurek DA.
Mizsak SA.
J. Antibiot.
1989,
42:
357
4 For a review, see Hodgkinson TJ.
Shipman M.
Tetrahedron
2001,
57:
4467
5
Zhao Z.
PhD Thesis
University of California;
Los Angeles:
1993.
For some alternative approaches to 1-azabicyclo[3.1.0]-hexanes, see:
6a
Buyle R.
Chem. Ind. (London)
1966,
195
6b
Laurent DA.
Chimia
1976,
30:
274
6c
Hudlicky T.
Frazier JO.
Seoane G.
Tiedje M.
Seoane A.
Kwart LD.
Beal CJ.
J. Am. Chem. Soc.
1986,
108:
3755
6d
Mulzer J.
Becker R.
Brunner E.
J. Am. Chem. Soc.
1989,
111:
7500
6e
Sasaki M.
Yudin AK.
J. Am. Chem. Soc.
2003,
125:
14242
Intramolecular conjugate additions involving aziridine nucleophiles are known. For example, see:
7a
Moran EJ.
Tellew JE.
Zhao Z.
Armstrong RW.
J. Org. Chem.
1993,
58:
7848
7b
Coleman RS.
Li J.
Navarro A.
Angew. Chem. Int. Ed.
2001,
40:
1736
7c ref. 5.
8 Prepared by oxidation of of 4-penten-1-ol (PCC, CH2Cl2, 3 h, r.t.), which was used directly in the olefination reaction without purification.
9
Hiebl J.
Kollmann H.
Rovenszky F.
Winkler K.
J. Org. Chem.
1999,
64:
1947
10
Selected Spectroscopic Data. Compound 6a/b: IR (neat): νmax = 3334, 2951, 1713, 1498 cm-1. 1H NMR (400 MHz, C6D6): δ = 7.22-7.15 (2 H, m, ArH), 7.11-7.00 (3 H, m, ArH), 5.87 (0.75 H, d, J = 8.5 Hz, NH), 5.73 (0.25 H, d, J = 8.0 Hz, NH), 5.14-4.98 (2 H, m, CH2Ph), 4.48 (0.25 H, dd, J = 8.5, 3.8 Hz, H-2), 4.40-4.33 (0.75 H, m, H-2), 3.41 (0.25 H, dd, J = 8.5, 3.5 Hz, H-3), 3.33 (0.75 H, s, CH3O), 3.29 (2.25 H, s, CH3O), 2.95 (0.75 H, t, J = 7.5 Hz, H-3), 2.02-1.98 (0.75 H, m, H-6), 1.91-1.85 (0.25 H, m, H-6), 1.61-1.43 (3 H, m, 2 × H-5, H-4), 1.31 (0.75 H, d, J = 5.2 Hz, H-7
exo
), 1.29 (0.25 H, d, J = 5.5 Hz, H-7
exo
), 1.18-0.88 (1 H, m, H-4), 0.56 (0.75 H, d, J = 3.3 Hz, H-7
endo
), 0.53 (0.25 H, d, J = 3.5 Hz, H-7
endo
). 13C NMR (100 MHz, C6D6): δ = 172.0 (CH3OCO), 171.4 (CH3OCO), 157.0 (NHCOO), 156.2 (NHCOO), 137.2 (ArC), 128.5-128.4 (ArCH), 67.1 (CH2), 67.0 (CH2), 66.9 (C-3), 66.0 (C-3), 59.9 (C-2), 58.1 (C-2), 51.9 (CH3O), 51.7 (CH3O), 41.0 (C-6), 40.0 (C-6), 28.2 (C-7), 28.0 (C-7), 26.1 (C-5), 25.0 (C-5), 24.3 (C-4), 22.6 (C-4). MS (ES+): m/z = 305 [MH+], 261, 91. HRMS (ES+): m/z calcd for C16H21N2O4: 305.1496; found: 305.1493 [MH+]. Compound 7a: IR (neat): νmax = 3319, 3172, 2947, 1712, 1527, 1435 cm-1. 1H NMR (400 MHz, C6D6): δ = 7.22-7.18 (2 H, m, ArH), 7.11-7.01 (3 H, m, ArH), 5.99 (1 H, d, J = 9.0 Hz, NH), 5.09 (1 H, d, J = 12.3 Hz, CHHPh), 5.01 (1 H, d, J = 12.3 Hz, CHHPh), 4.54 (1 H, t, J = 8.4 Hz, H-2), 3.33 (3 H, s, CH3O), 3.21-3.14 (1 H, m, H-3), 2.07-2.02 (1 H, m, H-6), 1.59-1.52 (1 H, m, H-5), 1.43-1.33 (1 H, m, H-5′), 1.26 (1 H, d, J = 4.8 Hz, H-7
exo
), 1.20-1.05 (2 H, m, H-4), 0.99 (1 H, d, J = 2.0 Hz, H-7
endo
). 13C NMR (100 MHz, C6D6): δ = 172.2 (CH3OCO), 156.2 (NHCOO), 137.2 (ArC), 128.4-128.3 (ArCH), 67.0 (CH2Ph), 65.4 (C-3), 56.8 (C-2), 51.7 (CH3O), 38.7 (C-6), 26.0 (C-5), 23.1 (C-7), 22.2 (C-4). MS (ES+): m/z = 305 [MH+], 91. HRMS (ES+): m/z calcd for C16H21N2O4: 305.1496; found: 305.1492 [MH+]. Anal. Calcd for C16H20NO4: C, 63.14; H, 6.62; N, 9.20%. Found: C, 63.10; H, 6.65; N, 8.80%. Compound 7b: IR (neat): νmax = 3368, 3181, 2948, 1710, 1499 cm-1. 1H NMR (400 MHz, C6D6): δ = 7.22-7.16 (3 H, m, ArH and NH), 7.11-6.99 (3 H, m, ArH), 5.08 (1 H, d, J = 12.0 Hz, CHHPh), 5.03 (1 H, d, J = 12.0 Hz, CHHPh), 4.33 (1 H, dd, J = 8.8, 6.6 Hz, H-2), 3.38-3.29 (4 H, m, CH3O and H-3), 2.15-2.09 (1 H, m, H-6), 1.51 (1 H, dd, J = 13.0, 8.0 Hz, H-5), 1.44-1.34 (1 H, m, H-5′), 1.22 (1 H, d, J = 5.0 Hz, H-7
exo
), 1.18-1.09 (1 H, m, H-4), 1.05-0.96 (1 H, m, H-4′), 0.93 (1 H, m, H-7
endo
). 13C NMR (100 MHz, C6D6): δ = 172.0 (CH3OCO), 156.6 (NHCOO), 137.3 (ArC), 128.5-128.2 (ArCH), 70.0 (CH2Ph), 63.7 (C-3), 57.7 (C-2), 51.8 (CH3O), 38.8 (C-6), 26.2 (C-5), 22.8 (C-7), 22.5 (C-4). MS (ES+): m/z = 305 [MH+], 261, 91. HRMS (ES+): m/z calcd for C16H21N2O4: 305.1496; found: 305.1496 [MH+].